Venus Medicine Research Centre (VMRC), the research and development (R&D) wing of Venus Remedies has been granted a patent for Elores, an antibiotic found effective against carbapenemase-resistant enterococci bacteria, by the Japanese Patent Office. It is expected to launch Elores in Japan by the end of 2015.
Dr Manu Chaudhary, Joint Managing Director, Venus Remedies and Director (Research), VMRC said, “This unique antibiotic adjuvant entity creates a synergistic effect due to its activity on multi-drug resistant extended spectrum beta lactamase and metallo beta lactamase (ESBL/MBL) producing gram negative bacteria. It prevents the development as well as the spread of bacterial resistance from one species to another. Clinical studies on more than 1,000 patients have indicated an over 30 per cent reduction in cost of therapy as compared to conventional therapies.”
Elores was recently recognised as the best innovation of 2013 by a team of experts from Stanford Business School, US, IC2 University of Texas, Austin, US and Lockheed Martin Foundation in collaboration with the union department of science and technology under the Indo-US joint science and technology innovation programme, 2013. It has also been selected among the top eight technologies to be commercialised in the US.
“Elores is a product with proven potential. The Japanese patent has given us exclusivity for the product in one of the world’s most important and lucrative healthcare markets up to 2025. Venus has already filed the common technical document with the European Union (EU) and is on the verge of getting MA grant for the product. Since EU and Japan have an understanding on the regulatory front, the product can be made available in the Japanese market within no time after receiving the MA grant from EU,” said Chaudhary.
Venus has received patents for this product from 46 countries, including the US, Australia, New Zealand, Russia, South Africa, South Korea, India and all major economies, including EU constituents.
EP News Bureau – Mumbai